The stock of Delivra Corp (CVE:DVA) hit a new 52-week high and has $0.81 target or 3.00% above today’s $0.79 share price. The 9 months bullish chart indicates low risk for the $15.99 million company. The 1-year high was reported on Dec, 1 by Barchart.com. If the $0.81 price target is reached, the company will be worth $479,700 more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 511,058 shares traded hands or 1109.55% up from the average. Delivra Corp (CVE:DVA) has risen 6.00% since November 1, 2016 and is uptrending. It has outperformed by 0.07% the S&P500.
More notable recent Delivra Corp (CVE:DVA) news were published by: Marketwired.com which released: “Delivra Corp. Issues $2020900, 6% Unsecured Convertible Debentures” on September 15, 2016, also Marketwired.com with their article: “Canopy Growth and Delivra Partner to Offer Innovative Therapeutic Cannabis …” published on September 19, 2016, Marketwired.com published: “Delivra Announces Q2 2016 Financial Results” on August 29, 2016. More interesting news about Delivra Corp (CVE:DVA) were released by: Marketwired.com and their article: “Delivra Enhances Performance of Celebrex(TM) (Celecoxib) — New Formulation …” published on October 03, 2016 as well as Marketwired.com‘s news article titled: “Delivra Powers Diabetic Wound Healing” with publication date: March 29, 2016.
Delivra Corp., formerly Whiteknight Acquisitions III Inc., is a developer of transdermal technologies for the delivery of pharmaceutical and natural molecules through the skin. The company has a market cap of $15.99 million. The Firm makes and sells natural topical creams under its brand names, LivRelief, which is indicated for conditions, including joint and muscle pain, nerve pain, circulation and wound healing, and LivSport brand, which is indicated for sports performance. It currently has negative earnings. The Company’s business is divided into two areas of focus: Consumer Healthcare Over the Counter Retail products, and Technology Licensing.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.